First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss
Genedrive PLC (AIM: GDR) Update on Point of Care Covid Test
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for
Novacyt S.A. (AIM: NCYT) Approval of COVID-19 test under CTDA legislation
Paris, France and Camberley, UK – 17 February 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate ® COVID-19 2G
Genedrive PLC (GDR.L) Investor Presentation
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.
Novacyt S.A. (NCYT.L) Strategy and Full Year 2021 Trading Update
Full-year revenue and EBITDA in line with expectations
Yourgene Health PLC (YGEN.L) DHSC contract award for COVID Winter surge testing
Third contract awarded under PHE National Microbiology Framework Agreement
Genedrive PLC (GDR.L) UK CTDA application for Genedrive® COV19-ID kit
Sensitivity and specificity data submitted meets MHRA requirements
Genedrive PLC (GDR.L) CE-IVD certification for Point-of-Care Genedrive®COV19-ID kit
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive®COV19-ID Kit has received CE-IVD
Genedrive PLC (GDR.L) POC kit submitted for CE-IVD certification
Point-of-care Genedrive®COV19-ID submitted for CE-IVD certification Sets new benchmark in speed, accuracy and ease of use
Novacyt S.A. (NCYT.L) Approval of COVID-19 test under CTDA legislation
Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 2
Genedrive PLC (GDR.L) Audited Final Results
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2021.
Genedrive PLC (GDR.L) Result of Open Offer
London, UK – 29 September 2021: genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces that it has conditionally raised total gross proceeds of approximately £1.1 million through the